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Abstract: 
Proton therapy has shown dosimetric advantages over conventional radiation therapy using photons. 
Although the integral dose for patients treated with proton therapy is low, concerns were raised about 
late effects like secondary cancer caused by dose depositions far away from the treated area. This is 
especially true for neutrons and therefore the stray dose contribution from neutrons in proton therapy is 
still being investigated. The higher biological effectiveness of neutrons compared to photons is the 
main cause of these concerns. The gold standard in neutron dosimetry is measurements, but performing 
neutron measurements is challenging. Different approaches have been taken to overcome these 
difficulties, for instance with newly developed neutron detectors. Monte Carlo simulations is another 
common technique to assess the dose from secondary neutrons. Measurements and simulations are used 
to develop analytical models for fast neutron dose estimations. This article tries to summarize the 
developments in the different aspects of neutron dose in proton therapy since 2017. In general, low 
neutron doses have been reported, especially in active proton therapy. Although the published 
biological effectiveness of neutrons relative to photons regarding cancer induction is higher, it is 
unlikely that the neutron dose has a large impact on the second cancer risk of proton therapy patients. 
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Neutron Dose and Its Measurement in Proton Therapy – Current State 1 
of Knowledge 2 
Abstract 3 
Proton therapy has shown dosimetric advantages over conventional radiation therapy 4 
using photons. Although the integral dose for patients treated with proton therapy is low, 5 
concerns were raised about late effects like secondary cancer caused by dose depositions 6 
far away from the treated area. This is especially true for neutrons and therefore the stray 7 
dose contribution from neutrons in proton therapy is still being investigated. The higher 8 
biological effectiveness of neutrons compared to photons is the main cause of these 9 
concerns. The gold standard in neutron dosimetry is measurements, but performing 10 
neutron measurements is challenging. Different approaches have been taken to overcome 11 
these difficulties, for instance with newly developed neutron detectors. Monte Carlo 12 
simulations is another common technique to assess the dose from secondary neutrons. 13 
Measurements and simulations are used to develop analytical models for fast neutron dose 14 
estimations. This article tries to summarize the developments in the different aspects of 15 
neutron dose in proton therapy since 2017. In general, low neutron doses have been 16 
reported, especially in active proton therapy. Although the published biological 17 
effectiveness of neutrons relative to photons regarding cancer induction is higher, it is 18 
unlikely that the neutron dose has a large impact on the second cancer risk of proton 19 
therapy patients. 20 
Introduction 21 
Proton therapy has become a well established cancer treatment modality in radiation 22 
oncology.1 It has shown dosimetric advantages over conventional radiation therapy using 23 
photons for many treatment sites2. Despite the high investment cost to establish a new 24 
proton therapy facility, the number of proton therapy centers worldwide has been 25 
increasing considerably. This development has given a lot more patients access to proton 26 
therapy. But it is still important to carefully select the patients who benefit the most from 27 
the advantages of proton therapy. For instance the precision of proton irradiations 28 
combined with the accuracy and reproducibility of positioning and immobilization of head 29 
and neck patients, has made lesions inside the head a very important indication for 30 
protons. On the other hand, one of the main advantages of clinical proton irradiations is the 31 
possibility to conform the deposited dose to the target volume. Thanks to the finite range of 32 
protons and the low entrance dose proximal to the target volume, the irradiated volume3 33 
and the integral dose can be considerably smaller than in photon radiation therapy. This 34 
has been shown in many treatment planning studies and confirmed by different 35 
measurements.2 One patient cohort which clearly can benefit from this are pediatric 36 
patients. Not only are most of the structures to be irradiated smaller than in adult patients 37 
and therefore the distances to organs at risk smaller, they are also at higher risk to develop 38 
late effects because of their long life expectancy and therefore a smaller integral dose is 39 
clearly beneficial for them. One of the possible late effects in pediatric radiation oncology is 40 






















































































the risk of radiation induced second primary cancers. This is equally important in proton 41 
and in photon radiation therapy. A smaller irradiated volume and a lower integral dose in 42 
proton versus photon radiation therapy would directly imply a lower risk of late effects for 43 
protons. Unfortunately, it is not as straight forward, as in both cases we are dealing with a 44 
mixed radiation field of different particles and energy spectra. Concerning late effects, 45 
beside the lower integral dose in proton therapy, the main difference is in the production of 46 
secondary neutrons. In proton therapy, secondary neutrons are mainly produced by 47 
interactions of protons in the therapy beam with the treatment delivery system and the 48 
patient. The dose deposited by protons and secondary charged particles is limited around 49 
the target volume, whereas secondary neutrons scatter further away and lead to a whole 50 
body neutron dose exposure. This dose is not part of the therapeutic dose and therefore is 51 
of direct importance for the induction of late effects. On the other hand for photon 52 
irradiations, neutrons are only produced in a considerable amount above an energy 53 
threshold. Only photon beams with a nominal energy of more than 10 MeV produce a 54 
considerable number of neutrons. Therefore, the neutron dose from many of the clinically 55 
used photon treatment plans is negligible for neutron induced late effects. In addition, the 56 
neutrons in high energy photon beams are mostly produced in the beam delivery system 57 
and only very few in the patient. So considering only these aspects, one could imply that the 58 
risk for late effects because of secondary neutron dose is lower for photons. These are only 59 
two examples that show how careful one must be when comparing the effects of neutrons 60 
in proton and photon radiation therapy. 61 
Since the beginning of clinical proton therapy, it has been known that neutrons are 62 
produced by interactions of the proton beam with matter. Although difficult to measure, it 63 
has been accepted that the absorbed dose for a patient from neutrons in proton therapy is 64 
small. The concerns about the neutron exposure arose from the facts, that the whole body 65 
of the patient gets irradiated and the biological effectiveness of neutrons is higher 66 
compared to photons and electrons. Studies which investigated the neutron biological 67 
effectiveness, the neutron radiation quality factor, or neutron radiation weighting factors 68 
showed varying results and the errors were big. Therefore it remained unclear how 69 
important the neutron contribution to the risk for late effects for a proton therapy patient 70 
actually is. An extensive assessment of neutron dose was presented in 2008 in the article 71 
by Xu et al.4 They wrote a review about dosimetry studies on external-beam radiation 72 
treatment with respect to second cancer induction. They say that it was confirmed that 73 
there is an increased cancer risk for patients after radiation therapy. Although it was not 74 differentiated between different radiation qualities. They conclude, that ‘many of the past 75 
dosimetry studies are based on inconsistent and sometimes confusing dose quantities and 76 
a systematic dosimetry methodology for quantifying secondary organ absorbed doses 77 needs to be developed in the future’. In addition, they point out that ‘the protection 78 
quantity, effective dose, should not be used for absolute risk assessment for specific patient 79 
or for epidemiological studies. Instead, organ- specific equivalent doses must be used and 80 documented’. They uncovered that some of the most important studies in the past were not 81 
able to contribute to the understanding of the dose-response curve, especially for relatively 82 
low doses. They conclude that further studies with reporting of organ-specific absorbed 83 
doses are necessary, for instance using computational phantoms and Monte Carlo 84 






















































































discusses the controversy about the impact of the neutron dose in proton therapy and what 86 
new epidemiological studies have contributed to the understanding. The task group 158 of 87 
the American Association of Physicists in Medicine (AAPM) published their findings on 88 
measurement and calculation of doses outside the treated volume from external-beam 89 
radiation therapy in an article in 2017.6 In a very systematic way, they present common 90 
practices and challenges in the quantification of stray doses in radiation therapy. They start 91 
with concerns with respect to nontarget radiation such as radiation induced second 92 
cancers. Further they describe the sources of out-of-field doses and the corresponding dose 93 
estimates for different treatment modalities. A lot of details are given about measurement 94 
approaches and all current measurement techniques in neutron dosimetry are discussed. 95 
Beside computational approaches, also very important key points in dose reporting, 96 
especially for neutron doses, are given. In the end they point out that as cancer treatments 97 
using radiation therapy modalities have shown increasing success, the issue of nontarget 98 
dose has become an important topic to understand. 99 
This article now tries to summarize the developments in the different aspects of neutron 100 
dose in proton therapy since 2017. For this review, 28 publications were included and 101 
structured into neutron measurements and detectors (16), and neutron dose distributions 102 
and their consequences (14), where two publications covered topics in both sections. 103 
Neutron Measurements and Detectors 104 
An important aspect of neutron dosimetry is the choice of the dose quantity. In photon 105 
radiation therapy it is common to report doses in the form of absorbed dose. Measurement 106 
devices are calibrated in absorbed dose and no biological weighting is necessary. In proton 107 
dosimetry, one has to be more careful, as the biological dose deposition mechanisms are 108 
different from photons and electrons. For the prescription of therapeutic doses in clinical 109 
proton therapy, it is established to use a constant relative biological effectiveness (RBE) for 110 
tumor control of 1.1.7 Therefore, the absorbed dose from protons is usually weighted by 111 
this RBE and given in Gy[RBE] to indicate that the biological effects have been accounted for. 112 
This keeps the formalism simple for proton dosimetry, although the RBE in principle is a 113 
function of particle type, energy, dose (rate), cell type, and biological endpoint. For 114 
neutrons it is more complicated. Many different metrics exist to quantify the neutron dose 115 
outside the treated volume. The AAPM task group 158 summarizes the implications of 116 these metrics for neutron dosimetry in their latest report: “Whichever metric is selected, 117 
the manner of this conversion should be explicitly stated. The interpretation of results from 118 
the literature is sometimes difficult because quantities are not used correctly or in a 119 
consistent manner for specific applications. Also problematic is the fact that many 120 
biologically weighted dose terms are designed for scenarios in radiation protection, not 121 
radiation therapy.”6 According to the International Commission on Radiological Protection 122 
(ICRP), the preferred way to handle high-LET radiation is to use absorbed dose weighted 123 
with an RBE for the investigated endpoint.8,,910 In the case of neutrons this is difficult, as 124 
the chosen endpoint might not have been measured and the reported neutron RBE ranges 125 
from less than 1 to over 200.11 This means that the RBE formalism for reporting neutron 126 
dose is currently not practical and therefore the AAPM task group 158 recommends to use 127 






















































































investigations on out-of-field neutron doses have reported their findings in neutron 129 
ambient dose equivalent, especially when measurements were done. Neutron ambient dose 130 
equivalent is an operational dose quantity for area monitoring and serves as an estimate of 131 
the effective dose of a person standing at the point of interest in the neutron radiation 132 
field.12 Although a neutron detector can measure a value of neutron ambient dose 133 
equivalent in a specific location, the actual measurement value represents a whole body 134 
neutron dose. Consequently, one needs to be careful and aware of the limitations when 135 
interpreting measurements of neutron ambient dose equivalent as point doses in the 136 
context of radiation therapy. 137 
A recent systematic investigation on out-of-field secondary neutron spectrometry and 138 
dosimetry using Bonner spheres has been published by Trinkl et al13. The neutron 139 
dosimetric properties and angular dependency for scanned proton beams of 75, 140, and 140 
200 MeV impinging on a PMMA phantom were compared. Neutron ambient dose 141 
equivalent values ranging from 0.3 𝜇Sv/Gy (75 MeV; 90°) to 24 𝜇Sv/Gy (200 MeV; 0°) were 142 
measured at a distance of 2 m from the isocenter. The highest neutron dose was measured 143 
downstream behind the phantom. The different Bonner spheres provided the possibility to 144 
determine the neutron energy spectrum at each measurement point. With this information 145 
they were able to identify an evaporation peak at 0° and 45° in the neutron fluence at 146 
around 1 MeV neutron energy. These neutrons contributed about 50% to the total neutron 147 
ambient dose equivalent, independent of the proton beam energy. 148 
Working group 9 of the EURADOS project published their work about three dimensional 149 
measurements of neutron and gamma-ray doses in a water phantom with 200 dedicated 150 
measurement positions using a variety of passive detectors.14 They used two types of 151 
polyallyldiglycol carbonate based track-etched detectors for the neutron dose 152 
measurements within the phantom. For the thermal neutron energy range, 153 
thermoluminescence detectors enriched with 6Li were used. The proton beam was a spread 154 
out Bragg peak with a modulation of 10 cm from a pencil beam scanning beam line with a 155 
maximal energy of 170 MeV. They quantified the neutron dose and compared the results 156 
for the different types of detectors at each measurement position. Perpendicular to the 157 
primary beam, they reported neutron dose equivalents of ~700 and ~60 𝜇Sv/Gy at a 158 
distance of 10 cm and 30 cm from the center of the spread out Bragg peak, respectively. 159 
The results were also compared with data from the literature. The comparison with 160 
neutron dose measurements published by Hälg et al.15 showed that the results of both 161 
experiments were in the same order of magnitude, which may be considered as a good 162 
agreement between two independent data sets. By comparing their results to a very similar 163 
experiment with a single field irradiation using a 20 MV photon beam16, Stolarczyk et 164 
al. found almost no difference in the measured neutron dose equivalents. On the other 165 
hand, the out-of-field secondary photon dose in proton spot scanning was up to three 166 
orders of magnitude lower than for photon radiation therapy using 6, 12, and 20 MV 167 
photon beams. This is in good agreement with previously published data15, therefore 168 
Stolarczyk et al. concluded that the contribution to the total out-of-field dose by secondary 169 
neutrons in proton spot scanning is small. 170 
In clinical proton therapy, there are two major techniques to produce the proton 171 






















































































are passive scattering or active scanning of the proton beam. As there are more 173 
components of the beam delivery system in passive scattering proton therapy which 174 
directly interact with the primary beam than in active scanning, neutron doses in passive 175 
proton therapy are higher by design. A special proton beam delivery technique, which can 176 
be seen as a kind of mixture of both delivery systems, is a so called wobbling nozzle beam 177 
delivery system. It uses magnets to apply the wobbling to the primary protons, but it also 178 
uses a scatterer to widen the beam. Liao et al. looked at a wobbling system, which consisted 179 
of wobbling magnets, a scatterer, ridge filter, fine degrader, dose monitor, flatness monitor, 180 
multi leaf collimator, compensator, and patient aperture.17 All these nozzle components are 181 
possible sources of secondary neutrons. It is therefore interesting to see, how the wobbling 182 
systems compares to active scanning and double scattering in terms of neutron exposure. 183 
Liao et al. measured their system using a WENDI-II detector to characterize the neutrons in 184 
terms of ambient dose equivalent and compared their findings to previously published data 185 
for other beam lines using wobbling18, double scattering18, or uniform scanning19. The 186 
detector was placed at different lateral distances from a solid water phantom, which was 187 
used to stop the primary beam with energies of 150 and 230 MeV. In addition, the influence 188 
of the primary beam energy, the field size, the width of the spread out Bragg peak, and the 189 
air gap on the neutron dose was investigated. Liao et al. were able to confirm that the 190 
neutron ambient dose equivalent increases with the proton beam energy and the spread 191 
out Bragg peak width, as well as that it decreases with the distance from the isocenter. 192 
They showed a clear increase in the neutron ambient dose equivalent with increasing 193 
wobbling diameter size. The neutron dose from the medium wobbling diameter was 2.1 194 
times larger than from the small diameter, whereas the large diameter was 3.3 times larger 195 
than the small one. Depending on the measurement conditions, they reported neutron 196 
ambient dose equivalents between 150 𝜇Sv to about 5⋅ 103𝜇Sv per treatment Gray. Liao et 197 
al. concluded that the measured neutron doses were similar to those of other facilities and 198 
the differences depend on the specific beam line design. They did not give a general 199 
conclusion, how wobbling systems compare to active and passive proton beam lines 200 
concerning neutron production. 201 
For investigations of any kind of dose, measurements are the gold standard. Despite the 202 
challenges in neutron dosimetry, it is also true for neutron dose studies. There has been a 203 
large number of publications involving neutron dose investigations in the last few years. 204 
This shows that it is still a topic of interest and the fact that more proton pencil beam 205 
facilities are being built, might be an indication that the scatter dose contribution of 206 
neutrons is not being neglected. The following Table 1 summarizes neutron dose 207 
measurements in proton therapy, which have been published recently. Some of the 208 
publications in the table have been mentioned above, but not all articles could be included 209 
in the discussion. If several measurement conditions for neutron dose were reported, only 210 
part of the results were included in the table. In Figure 1 and Figure 2, the neutron doses 211 
from Table 1 are visualized for the angles 0° and 90° as a function of distance from 212 
isocenter. The different beam delivery systems are drawn as different symbols and a 213 
separation into low energy (<200 MeV) and high energy (>200 MeV) is shown by open and 214 






















































































Table 1: Summary of neutron dose equivalent measurements per treatment dose from 216 
recently published literature. The given angle is relative to the proton beam direction. If 217 
several distances and angles are given in one row, each distance corresponds to one angle and 218 












Neutron Dose 𝜇Sv/Gy 
        
Ciocca et 
al.20 
Bb PBS 86 2.3 6.4 90 68 
Han et al.21 W-II S 217.8 5 50, 100, 
150 
0 474, 308, 205 
Islam et 
al.22 
ET US 78, 162, 
226 
0 17.5 90 1.24⋅ 103, 
4.05⋅ 103, 
6.64⋅ 103 
Lee et al.23 WII W 190 10 50, 100, 
200 
90 1.38⋅ 103, 
1.03⋅ 103, 
512 
 W-II LS 190 10 50, 100, 
200 
90 20, 10, 5 
 W-II PBS 190 10 50, 100, 
200 
90 16, 9, 5 
Liao et al.17 W-II W 150 6 50, 100, 
150, 225 
0 1.03⋅ 103, 
781, 573, 297 
 W-II W 230 6 50, 100, 
150, 225 




 W-II W 150 10 50, 100, 
150, 225 
0 1.20⋅ 103, 
860, 652, 376 
 W-II W 230 10 50, 100, 
150, 225 






TEPC PBS 146 10 100 0, 45 79, 41 
Lin et al.25 W-II W 190 0 50, 100, 
150, 200 









































































































W-II S 250, 25 
cm* 





 W-II S 250, 25 
cm* 
20 20, 40, 60, 
80, 100, 
150 





ET PBS 170 10 9, 14, 19, 
24, 29, 34, 
39 
90 1.73⋅ 103, 
770, 280, 









 BS PBS 140 0 200 0, 45, 
90, 
135 
5.9, 3.2, 1.6, 
1.5 
 BS PBS 200 0 200 0, 45, 
90, 
135 
24, 11, 5.3, 
4.1 
 BS PBS 118, 
5cm RS 
0 200 0, 45, 
90, 
135 
2.4, 2.8, 1.2, 
1.2 
Abbreviations: 220 
W-II: WENDI-II, Bb: Bubble detector, ET: Etch track detector, BS: Bonner sphere, TEPC: 221 
Tissue equivalent proportional counter, W: Wobbling, S: Scattering, PBS: Pencil beam 222 
scanning, US: Uniform scanning, LS: Line scanning, RS: Range shifter 223 
 224 
Figure 1: Neutron dose equivalent in 𝜇Sv per treatment Gy as a function of distance from 225 
isocenter along the direction of the primary proton beam (Angle 0°) from the publications in 226 
Table 1. The different beam delivery systems are drawn as different symbols. Open and filled 227 
symbols show low or high energy proton beams. Experimental data points have been slightly 228 
shifted around their distance for better visibility. 229 
 230 
Figure 2: Neutron dose equivalent in 𝜇Sv per treatment Gy as a function of distance from 231 
isocenter perpendicular to the direction of the primary proton beam (Angle 90°) from the 232 
publications in Table 1. The different beam delivery systems are drawn as different symbols. 233 






















































































have been slightly shifted around their distance for better visibility. For comparison, minimum 235 
and maximum measured neutron doses for scattering proton therapy from the AAPM TG-158 236 
report were added.6 237 
As discussed earlier in this section, neutron dosimetry is no straight forward task. 238 
Investigating neutrons in radiation therapy always means dealing with mixed fields. 239 
Neutron detectors therefore not only have to cover a wide energy range, but also the 240 
sensitivity to other types of radiation should be as low as possible. In radiation therapy, the 241 
goal of measurements, for instance neutron dose, is usually to quantify the radiation 242 
exposure for patients or for staff members. Especially in neutron dosimetry, in-vivo 243 
measurements are very challenging. And for obvious reasons, most research experiments 244 
cannot be performed with in-vivo measurements. Therefore, the patient is commonly 245 
replaced with a so called phantom. Common phantom materials are water- or tissue-246 
equivalent plastics. Tissue equivalence is a very important point in this context. As the 247 
patient is replaced with phantom material, it is of utmost importance that the chosen 248 
material behaves like real tissue within measurement uncertainties. The International 249 
Commission on Radiation Units and Measurements (ICRU) defines tissue-equivalent 250 
material in their report 3028: “A material, the absorption and scattering properties of 251 
which, for a given irradiation, simulate as nearly as possible those of a given biological 252 
material, such as soft tissue, muscle, bone or fat. Water is usually the best soft tissue-253 equivalent material for x and gamma radiation.” The property of tissue equivalence is 254 
widely used in radiation therapy, but the fact that it is dependent on the type of radiation, is 255 
rarely discussed. Most commercially available tissue-equivalent phantoms are made for 256 
photon irradiations. For neutron measurements in proton therapy, it is not a priori clear 257 
that a tissue- or water-equivalent phantom made for photon irradiations, also is a good 258 
substitute for tissue in a proton beam. Different phantom materials have been investigated 259 
for tissue-equivalence in regard to neutrons29,30 and choosing the appropriate phantom 260 
material should be part of any investigation that includes neutron measurements. Different 261 
approaches have been taken to overcome these difficulties in neutron dosimetry and 262 
progress has been made in developing new means of estimating the true neutron dose in 263 
the last years. In this section, some of the new developments in the field of neutron 264 
detectors are presented. The group of Ytre-Hauge et al. tried to overcome the 265 
disadvantages of passive detectors and the large physical size of active neutron detectors. 266 
They present a first application of a neutron detector based on registration of radiation 267 
induced effects in Static Random Access memories (SRAMs) in order to perform neutron 268 
measurements inside phantoms with a fast readout system.31 The measurement device was 269 
placed in a water phantom and irradiated with a proton pencil beam of 178 MeV. A neutron 270 
energy response model was developed for the new system to increase the accuracy in the 271 
neutron energy range typical in proton therapy. This allowed to determine the internal 272 
neutrons from proton pencil beam scanning. To benchmark the new detector system, 273 
Monte Carlo simulations and measurements with thermoluminescence detectors were 274 
performed. They found that the detection threshold of 3 MeV of their new system is low 275 
enough to capture approximately 90% of the neutron dose in pencil beam scanning proton 276 
therapy. The investigated neutron spectra had a small impact on the detector response and 277 
they suggest the possibility of position-specific calibration factors. They conclude that the 278 






















































































the SRAM detector measurements in combination with the neutron energy response 280 
model.31 The MONDO (MOnitor for Neutron Dose in hadrOntherapy) project is developing a 281 
neutron tracking detector.32 It should be able to investigate neutrons in the energy range of 282 
20 to 400 MeV. By tracking recoil protons in a three dimensional matrix of scintillating 283 
fibers, the system is able to determine flux, energy spectra, and angular distribution of the 284 
neutrons. The selection criteria for the recoil protons is two consecutive neutron elastic 285 
scattering interactions. The detector properties were optimized using Monte Carlo 286 
simulations and the findings presented in a publication. In addition, calibration and 287 
efficiency measurements were performed using a prototype detector in a clinical proton 288 
beam. Giacometti et al. conclude that the experimental and simulation results are in good 289 
agreement. In the future, they want to include particle energy loss and timing information, 290 
to improve the detection capability of the MONDO tracker. Tagawa et al. developed a novel 291 
neutron camera consisting of eight units of a plastic scintillator and a compact 292 
photomultiplier tube.33 The camera can visualize neutron sources in real time and show 293 
their direction and intensity for applications in proton therapy. Neutron induced recoil 294 
protons are registered and their energy is measured. Using a time of flight analysis, the 295 
energy of the incoming neutron is calculated. Using the information of the recoil proton and 296 
the neutron, the direction of the neutron source is determined. The time of flight 297 
information as well as pulse shape discrimination are used to distinguish between 298 
incoming photons and neutrons. In their publication, they showed that a 252Cf neutron 299 
source could successfully be imaged with an angular resolution of 15.5° full width half 300 
maximum. A brass phantom was irradiated using a 70 MeV proton beam in two different 301 
positions relative to the neutron camera. The emitted neutrons were detected by the 302 
camera and the location of the brass phantom was successfully determined. In order to 303 
improve the neutron detection in a proton therapy environment, they increased the energy 304 
threshold to take advantage of the strongly reduced photon background above 10 MeV. A 305 
new Bayesian approach to get spectral information from neutron measurements using 306 
Bonner spheres was published by Dommert et al. 34 Typically, neutron spectrum 307 
information from Bonner sphere measurements is acquired using unfolding methods. The 308 
disadvantage of this procedure is the difficulty to get reliable estimates of uncertainties. 309 
The Bayesian approach is supposed to overcome this difficulty and improve the results of 310 
wide range neutron energy measurements, which only Bonner spheres are capable of. A 311 
new parameterized model was introduced to analyze stray neutrons in proton therapy. In 312 
order to build a parameterized model of the neutron spectrum, a superposition solution of 313 
a thermal peak, an intermediate region, a fast energy peak, and a high energy peak is 314 
necessary. The Bayesian analysis then requires a likelihood function and prior distributions 315 
for the parameters. The approach has been experimentally validated with measurements at 316 
an experimental beam line at a proton therapy facility. The neutron source was a brass 317 
target of simple geometry irradiated by the experimental horizontal proton beam of 224 318 
MeV without a complicated therapy nozzle. The results of the Bayesian parameter 319 
estimation were in good agreement with established unfolding codes based on Monte Carlo 320 
calculated neutron spectra. The group of Chung et al. looked into a neutron detector based 321 
on solid plastic scintillators, which can distinguish neutrons from photons.35 They use a 322 
pulse shape analysis of the scintillation light for the particle discrimination. The specific 323 
plastic scintillator used, EJ299-33, has the potential to detect neutrons with energies up to 324 






















































































liquid scintillators. The group performed measurements with different radiation sources, 326 
namely 60Co, 137Cs, and 241AmBe in order to calibrate the device. The measurement data 327 
was also used to optimize the pulse shape discrimination parameters. The device was also 328 
used to measure high energy neutrons produced by a passively scattered proton beam of 329 
60 MeV. They were able to successfully register neutrons and photons, but they conclude 330 
that simulations are needed to further study the neutron energy calibration. 331 
Neutron Dose Distributions and Their Consequences 332 
Assessing the neutron dose distribution is not a straight forward task. There are different 333 
possible approaches and each has its own challenges and limitations. The gold standard in 334 
any form of dosimetry is to perform measurements (see section Neutron Measurements 335 
and Detectors). Especially in neutron dosimetry, Monte Carlo based simulations have been 336 
gaining importance. Analytical models to approximate the neutron dose distribution are 337 
usually based on measurements, Monte Carlos simulations, or both. Analytical models are 338 
developed for instance in order to integrate a neutron dose calculation into a treatment 339 
planning system or for research purposes. 340 
In radiation therapy, neutrons are usually secondary particles produced by the interaction 341 
of primary beam particles with materials in the beam path. Therefore, in order to 342 
investigate neutrons, one has to deal with mixed radiation fields. This is part of the 343 
difficulties in neutron dosimetry, as an ideal detector,which only registers neutrons is not 344 
available. In a computer simulation on the other hand, it is very well possible to separate 345 
the different constituents of a mixed radiation field. Monte Carlo simulation toolkits have 346 
been available for many years now, a lot of them tailored for particle transport applications 347 
in high energy physics applications. But these toolkits were not designed for such low 348 
energy applications, as are needed in medical physics. Only in recent years the developers 349 
of these simulation packages have been aware of the needs for simulations in medical 350 
physics. Thanks to these developments and the advances in computer hardware, Monte 351 
Carlo simulations for radiation therapy purposes have become well established. Especially 352 
in proton therapy, or more general in particle therapy, Monte Carlo simulations play an 353 
important role, for instance for beam line design, shielding verification, patient dose 354 
calculation, and of course for secondary neutron investigations. In order to get precise 355 
results when performing Monte Carlo simulations, it is important to include as many 356 
details of the irradiation situation as possible. For neutron simulations it is especially 357 
important to include the beam modifying devices in the treatment nozzle. Trinkl et al.13 358 
identified the nozzle components and their materials as the most important sources of 359 
neutrons in proton therapy. It is therefore absolutely necessary to include these parts with 360 
as much details as possible in any simulation where neutrons are involved. 361 
In a study by Prusator et al., Monte Carlo simulations of neutron dose were reported and 362 
benchmarked with measurements carried out using a WENDI-II detector for a passive 363 
scattering proton therapy system.27 The goal of the work was to verify the shielding of the 364 
MEVION S250 proton system, which is mounted on a rotating gantry inside the treatment 365 
room. This single room design is specifically challenging for radiation shielding, both 366 
concerning the patient and the staff. They used several neutron sources in their Monte 367 






















































































beam delivery nozzle, and the patient. The patient was represented by a cubic water 369 
phantom. The concrete vault was included in the simulation geometry, which is essential 370 
for shielding investigations, but also for in-room neutron studies, as neutrons bounce back 371 
from the walls. The proton beam used for the shielding simulations had an energy of 250 372 
MeV with a range between 15 and 30 cm and modulation width between 10 and 20 cm. The 373 
angular dependence of neutron fluences and energy spectra were simulated and neutron 374 
ambient dose equivalent per incident proton was calculated using fluence to dose 375 
conversion factors. They found that the cyclotron had the largest neutron contribution, 376 
followed by the nozzle, and the water phantom. The largest neutron doses were found in 377 
the direction of the primary proton beam and for the smallest field sizes. The comparison 378 
of the simulation and the measurement showed the same trends in all measurement 379 
locations, but the simulation results were about an order of magnitude higher than the 380 
measurements. As an explanation for this difference, they suspect the neutron point source 381 
model of the cyclotron to be too simplistic. 382 
The influence of field arrangement in proton pencil beam scanning radiation therapy on 383 
organ doses from secondary radiation was investigated in a recent paper.36 Treatment 384 
plans using a single lateral or vertex field were created for an adult female and a pediatric 385 
patient. The involved proton beam energies ranged from 80 to 126 MeV. Whole body CT 386 
scans of the patients with 15 delineated organs at risk and target volumes were included in 387 
the Monte Carlo model. The simulation scored absorbed dose and neutron equivalent dose 388 
was calculated using the radiation weighting factors from report 103 by the International 389 
Commission on Radiological Protection (ICRP). Additionally, the neutron energy fluence 390 
spectra were scored in the included organs at risk. The organ absorbed doses were 391 
reported as the sum of all secondary particles. Only the neutron equivalent dose was 392 
reported separately. Ardenfors et al. concluded that the doses from secondary particles in 393 
proton pencil beam scanning for brain tumors are relatively low and in the order of mSv. In 394 
general, the organ doses for the pediatric patient were higher compared to the adult 395 
patient, but the differences were small in absolute terms. For the field arrangement they 396 
found that the vertex field caused higher organ doses in most organs at risk, but the 397 
variations were small as well. They therefore say that the field arrangement does not lead 398 
to large variations in the out-of-field dose for proton pencil beam patients. 399 
Proton pencil beams with primary energies of 70, 150, and 200 MeV were investigated in a 400 
paper by Yeo et al. to quantify the spatial and angular distribution of secondary neutrons.37 401 
The proton beams were impinging on phantoms made of 24 different materials with 402 
dimensions 30x30x30 cm3. For the secondary neutrons, only the production was simulated 403 
and the energy, momentum, and position of production were scored. No transport of the 404 
neutrons in the phantom materials was simulated. A lethality factor was defined as the 405 
track-summed RBE of the neutrons in each voxel to quantify the maximum risk of localized 406 
DNA damage from neutrons at production.37 The RBE values used for this assessment were 407 
taken from another publication.38 In that study, Baiocco et al. combined neutron transport 408 
simulations using Monte Carlo with biophysical track structure calculations to evaluate 409 
DNA damage. Extensive calculations of neutron induced secondary charged particles, their 410 
contribution to the total neutron dose, as well as neutron energy and location dependent 411 






















































































and DNA double strand break cluster induction. Yeo et al. summarize their findings that 413 
most of the neutrons produced in any of the tissue phantoms have an energy below 1 MeV 414 
and are predominantly forward directed. The forward direction is more pronounced for 415 
higher beam energies. Neutrons in this intermediate energy range have a high RBE and 416 
they conclude that these can result in a high localized damage. They also say that the 417 
proton beams in treatment planning should not be directed towards dense structures like 418 
cortical bone, because these showed the highest lethality factors in their study. In practical 419 
terms this means that if two proton treatment plans have the same tumor control 420 
probability and the normal tissue complication probability is very similar too, the 421 
treatment plan that better avoids dense structures, should be preferred. 422 
Monte Carlo simulations were also used to investigate a wobbling proton beam delivery 423 
system (see also section Neutron Measurements and Detectors) concerning the neutron 424 
production.25 Lin et al. used a WENDI-II detector to benchmark their simulations. The 425 
Monte Carlo model contained all the major beam delivery devices: vacuum window, profile 426 
monitor, beam dose monitor, fine degrader, snout, aperture, multi leaf collimator, and a 427 
range compensator. Specifically for the wobbling system, it also contained two dipole 428 
wobbler magnets, a scatterer, and a ridge filter. The investigated proton beam energy was 429 
190 MeV. The ridge filter was set to produce a 10 cm spread out Bragg peak. Neutron 430 
fluences were scored at different locations with distances up to 200 cm from the isocenter 431 
and with angles of 0, 45, and 90° relative to the primary beam direction. The simulated 432 
neutron fluences were converted to neutron ambient dose equivalent and neutron dose 433 
equivalent using conversion coefficients from literature. The calculation and measurement 434 
of neutron ambient dose equivalent along the lateral direction showed good agreement. 435 
They were able to identify a larger number of high energy neutrons in the forward 436 
direction of the proton beam, which were produced by the intranuclear cascade. The 437 
largest number of neutrons around 1 MeV coming from the evaporation process were 438 
found at an angle of 90°. Like Liao et al.17 (see section Neutron Measurements and 439 
Detectors), Lin et al. were able to confirm that the neutron dose decreased with increasing 440 
distance from the isocenter. In addition, they found that the neutron dose generally 441 
increased with an increase in the angle relative to the proton beam. At 90° angle, they 442 
found a difference in the neutron dose depending on the direction relative to the multi 443 
leave collimator. In the direction of the movement of the multi leave collimator, the neutron 444 
dose was found to be lower. Lin et al. conclude that care should be taken with the 445 
positioning of the patient, if the patient axis is at a 90° angle of the proton beam, because of 446 
the shielding effect of the multi leaf collimator. In addition, they say that the neutron dose 447 
level in their study was lower than that of passive scattering nozzles, but higher than that 448 
of a pencil beam scanning system.25 449 
Measurements and in particular Monte Carlo simulations can give detailed insights into an 450 
investigated topic. Therefore they are the preferred methods for neutron dose 451 
determination. The downside is that they are time and resource intensive.39 Commercial 452 
solutions for Monte Carlo simulations in radiation therapy are sparsely available and they 453 
are usually tailored to a specific task. And even with commercial tools, full Monte Carlo 454 
simulations are still very time consuming. Analytical models can fill this gap. They can be 455 






















































































perform the calculations can be in the order of minutes, which is acceptable even for daily 457 
tasks. Using an analytical model for whole body stray dose calculations, for instance the 458 
neutron dose from proton beams, can facilitate the comparison of different clinical proton 459 
treatment plans. Consequently, not only the conformality of the primary dose to the target 460 
volume calculated by the treatment planning system can be compared, but also the amount 461 
of neutron dose to distant organs at risk can be evaluated in the treatment planning 462 
process. This would be a further step in trying to minimize treatment-related late effects. 463 
Newhauser et al. published a review in 2018 on analytical models of stray radiation 464 
exposures.41 They looked into stray doses from proton and photon beam radiation therapy. 465 
For proton therapy, they distinguished three categories of analytical models: collimator 466 
scattered protons, external neutrons, and internal neutrons. For stray dose investigations, 467 
only the neutron models are of interest, as collimator scattered protons do not contribute 468 
to the stray dose away from the target volume. External neutrons refer to neutrons 469 
produced in the proton beam nozzle by nuclear interactions of the primary protons with 470 
the beam forming devices, whereas internal neutrons refer to neutrons produced by 471 
nuclear interactions within the patient. In active proton therapy, for instance using proton 472 
pencil beam scanning, only models for internal neutrons are needed, as only very few 473 
neutrons are produced in the beam line components. On the other hand in passive proton 474 
therapy, for example double proton scattering beam lines, models for external and internal 475 
neutrons are needed, because the primary proton beam interacts with components in the 476 nozzle, such as the scatterers and the field specific aperture, and with the patient’s body. 477 
Therefore, the neutron stray dose from passively scattered proton treatments is 478 
intrinsically higher compared to scanned-beam techniques, which has been shown by 479 
measurements and Monte Carlo simulations in the past. In the last two years two new 480 
analytical models for neutron dose in proton therapy were developed. Schneider et al. 481 
integrated neutron absorbed dose and neutron dose equivalent dose kernels for pencil 482 
beam scanning into the treatment planning system at Paul Scherrer Institut.42 The kernels 483 
were generated using a full Monte Carlo model of their pencil beam scanning gantry with 484 
proton beams impinging on a water phantom. The results for the proton dose calculation 485 
and the neutron dose estimation for two patient cases can be found in Figure 3 486 
(ependymoma) and in Figure 4 (cranio-spinal). In another publication, an extension of the 487 
model for neutron energy, quality factor, and RBE was introduced.43 Gallagher and Taddei 488 
used the model for external neutrons from Schneider et al.44 and modified it to apply it in a 489 
clinically realistic environment.45 They adjusted the model to account for the treatment 490 
field parameters of two pediatric patients and compared the calculations to previously 491 
published Monte Carlo simulations. They found that the accuracy of the adjusted model to 492 
be sufficient for the purpose of estimating the risks of radiogenic cancers and that they 493 
were able to reproduce the neutron stray dose results from full scale Monte Carlo 494 
simulations within a factor of two.45 In a follow-up paper, Gallagher and Taddei extended 495 
their model for external neutrons to internal neutrons using measurements and Monte 496 
Carlo simulations to determine equivalent dose.46 In their review article, Newhauser et 497 
al. concluded that rapid progress has been made in the last few years toward 498 
understanding the systematics of how stray exposures depend on a myriad of treatment 499 
factors and that it was demonstrated that it could be possible to prospectively calculate 500 






















































































years about modelling neutron doses in proton therapy has shown that this trend is 502 
continuing. 503 
 504 
Figure 3: Proton dose distribution for the pediatric ependymoma (case 1) planned with 160 505 
MeV protons in a. The corresponding neutron dose distributions in mGy per fraction are 506 
shown in b-d. From Schneider et al.42 507 
 508 
Figure 4: Proton dose distribution of the cranio-spinal irradiation (case 2) shown in a. The 509 
corresponding estimated neutron dose is shown in b-d, with figure c showing the neutron dose 510 
at the level of the breast and figure d at the level of the thyroid. From Schneider et al.42 511 
To cover a target volume with dose in proton therapy, proton beams with many different 512 
energies are needed. A common technique to transform the small number of distinct 513 
primary proton energies from the accelerator into many therapeutic proton energies is 514 
called range modulation. This has traditionally been done by a range modulator wheel or 515 
by range-shifter plates in the treatment nozzle. More recent proton beam delivery systems 516 
try to avoid the need of these devices and perform different methods of energy selection, or 517 
place them upstream outside of the treatment room, so the secondary neutrons from this 518 
process can be shielded.47 The range modulation devices change the proton energy by 519 
varying the amount of material traversed by the protons before impinging on the patient. 520 
This beam forming device is one of the possible neutron sources inside the proton nozzle. 521 
Trinkl et al.13 compared two proton beams with and without range modulation, both with 522 
similar ranges. A range-shifter of 5 cm inside the treatment nozzle increased the neutron 523 
dose 45° in relation to the primary beam by a factor of 7.2 for the beam of 118 MeV 524 
compared to the non-modulated beam of 75 MeV. To optimize a treatment plan in proton 525 
therapy in terms of neutron dose, it is therefore important to minimize the use of range 526 
modulation. Not only the amount of range modulation, which has to be applied, also the 527 
primary proton energy has a direct influence on the neutron dose. Trinkl et al.13 also 528 
showed that the neutron dose increases with the proton beam energy. They observed a 529 
maximal increase by a factor of 50 in neutron ambient dose for the maximal energy of 200 530 
MeV compared to the lowest energy of 75 MeV in beam direction behind the phantom. 531 
In order to increase the dose conformity to the target volume, different beam shaping 532 
devices have been developed and tested in proton therapy over the years. It has been 533 
shown for instance for proton pencil beam scanning, that a Dynamic Collimation System 534 
(DCS) can provide superior target conformity and healthy tissue sparing when compared 535 
with conventional pencil beam scanning treatment modalities.48 But every additional 536 
component in the proton treatment nozzle is a potential source of secondary neutrons. 537 
Therefore, not only the effect on dose conformity should be evaluated, but also the amount 538 
of secondary neutron production. A current approach was investigated by Smith et al.51 for 539 
intracranial pencil beam scanning proton therapy. They used Monte Carlo simulations to 540 
characterize a DCS based on trimmer blades. Single-field uniform dose and intensity-541 
modulated proton beams for a dual-field chordoma treatment plan with and without 542 






















































































ambient dose equivalent using the DCS of 970 𝜇Sv/Gy for the right lateral and 1.37⋅544 103𝜇Sv/Gy for the apex single-field uniform dose (SFUD). Without the DCS, the neutron 545 
dose was reduced by about a factor of two to 570 𝜇Sv/Gy and 670 𝜇Sv/Gy, respectively. For 546 
the intensity-modulated proton plan, a total of 1.24⋅ 103𝜇Sv/Gy was found using DCS and 547 
710 𝜇Sv/Gy without DCS, again a substantial reduction. The group of Smith et al. also 548 
looked at excess relative risk and lifetime attributed risk. Although the relative increase in 549 
neutron dose and excess relative risk with the application of this specific DCS is large, they 550 
conclude that the lifetime attributed risk from this neutron exposition is minimal and that 551 
the reduction in acute side effects due to the improved conformity far outweighs the 552 
additional risk from the produced neutrons. 553 
Reducing radiation induced late effects while keeping the tumor control rates high, is a 554 
current topic of interest in radiation oncology. With a growing number of long-term cancer 555 
survivors, it is more and more important to have a better understanding of the risk of 556 
cancer induction by ionizing radiation. As mentioned earlier, this is especially important for 557 
pediatric patients. In case of proton therapy, radiation induced second cancer can occur 558 
from any of the radiation types in the mixed field. Because of the large uncertainty in the 559 
radiation weighting factors of neutrons, the focus of many second cancer studies is on the 560 
dose from secondary neutrons. A study on human breast cells was published in 2017 561 
where different radiation qualities, including neutrons, were investigated. Juerß et 562 
al. irradiated MCF10A cells with doses up to 2 Gy with broad energy spectrum neutrons 563 
(<En> = 5.8 MeV), monoenergetic neutrons (1.2 MeV, 0.56 MeV), and with a mixed field of 564 
photons and neutrons (<En> = 70.5 MeV) produced by a 190 MeV proton pencil beam 565 
impinging on a water phantom.52 Radiation-induced DNA double strand breaks and the 566 
clonogenic survival were determined after irradiation. Using X-rays as a reference (220 kV, 567 
1 mm Al, 0.25 mm Cu, 0.45 mm Sn filter), the observed radiation effects of neutrons were 568 
compared using the concept of RBE.52 Also two different dose rates were investigated. 569 
Monte Carlo calculations were performed to determine the neutron spectra in the liquid 570 
cell suspensions and to account for scattered neutrons in the sample holder. The 571 
determined RBE values based on clonogenic survival after irradiation were 4.97 and 3.75 572 
(monoenergetic neutrons 0.56 and 1.2 MeV), 2.09 (mixed photon neutron field), and 2.06 573 
and 1.99 for high and low dose rate (broad energy spectrum neutrons), respectively. 574 
Double strand break based RBE values were 7.95 and 3.98 (monoenergetic neutrons 0.56 575 
and 1.2 MeV), 4.47 (mixed photon neutron field), and 4.57 and 5.25 for high and low dose 576 
rate (broad energy spectrum neutrons), respectively. They conclude that the RBE values 577 
are coherently increasing for decreasing neutron energy in the investigated energy range. 578 
The exposure to the mixed photon - secondary neutron field yield RBE values as high as for 579 
medium-energy neutrons.52 580 
The concept of weighting the energy deposition in tissue by neutrons is based on physical 581 
and biological properties. For instance the particle energy as the physical property and the 582 
biological context would be for example the investigated end point. The group of Imaoka et 583 
al. looked into age as a biological factor for neutron RBE determination.53 From the 584 
perspective of radiological protection, age is an important aspect, which influences 585 
radiation-related cancer risk. Their goal was to investigate the age effect for neutrons, 586 






















































































the influence of age on the effect of accelerator-generated fast neutrons (mean energy 588 
about 2 MeV) in an animal model of breast carcinogenesis. Female Sprague-Dawley rats at 589 
1, 3, and 7 weeks of age were irradiated with fast neutrons at absorbed doses of 0.0485–590 
0.97 Gy. All animals were kept under specific pathogen-free conditions and screened 591 
weekly for mammary tumors by palpation until they were 90 weeks old. Tumors were 592 
diagnosed based on histology. Mathematical modeling was used to analyze mammary 593 
cancer incidence, collectively using data from this study and a previously reported 594 
experiment on a 137Cs photon beam. They found that the results indicate that neutron 595 
irradiation elevated the risk of palpable mammary carcinoma with a linear dose response, 596 
the slope of which depended on age at time of irradiation. The RBE of neutron radiation 597 
was 7.5 ± 3.4, 9.3 ± 3.5 and 26.1 ± 8.9 (mean ± SE) for animals exposed at 1, 3, and 7 weeks 598 
of age, respectively. These results indicate that age of the animal is an important factor 599 
influencing the effect of fast neutrons on breast cancer risk.53 600 
A more general article about second cancer risk after particle therapy was published by K. 601 
R. Trott.54 He discusses the radiobiology of the unwanted effects of radiation therapy, the 602 
dependence of radiation induced second cancers on exposed organ, dose, dose distribution, 603 
age, and gender, the variable LET along the particle track and the RBE of secondary 604 
neutrons, as well as the ANDANTE project,55 which investigated the relative risk of 605 
induction of cancer from exposure to neutrons compared to photons. Trott elaborates that 606 
the absolute risk of radiation-induced second cancer is in the order of 1% for adult patients 607 
who were treated with methods which caused relatively high out-of-field doses. It is 608 
generally accepted that proton therapy has smaller out-of-field doses. Therefore, Trott 609 
states that it is very unlikely that patients treated with highly conformal particle therapy 610 
are at a higher risk for radiation induced second cancer than those patients treated with 611 
photons, whichever reasonable RBE is chosen. He adds that most of these patients will have 612 
a higher second cancer risk than those who were treated 20 or more years ago, but this will 613 
be due to their longer life expectancy because they were cured. For childhood cancer 614 
patients, Trott sees reasons for concern, because there is still a potential risk of second 615 
cancer from stray doses in proton therapy. But he also writes that although the possible 616 
undesired consequences for children are more complex and manifold than in adult 617 
patients, they will benefit from the better focusing of the radiation dose in the target by 618 
particle radiation therapy. He concludes that this benefit may far outweigh the still 619 
hypothetical second cancer risk from neutrons produced by particle beams in pediatric 620 
radiotherapy. 621 
Conclusions 622 
The stray dose contribution from neutrons in proton therapy is still being investigated by 623 
several research groups. Since 2016, the biggest reported progress has been in the field of 624 
neutron detector development. Several promising new neutron detectors are being 625 
developed and it will be interesting to see, how they will change the reporting of neutron 626 
doses in proton therapy. For now, performing neutron measurements stays challenging. 627 
Also more studies have been published since 2016 where neutron doses were either 628 
measured or simulated, but no clear new insights were reported. The comparison of 629 






















































































affect the results of neutron studies, as for instance the measurement setup, beam line 631 
design, or neutron detectors to just name a few. This leads to large differences in the 632 
reported neutron doses and therefore, drawing specific conclusions is difficult. 633 
Nevertheless, recent studies in this field were able to confirm earlier findings about the 634 
neutron dose exposure of proton therapy patients. The largest difference in neutron dose 635 
comes from different treatment techniques and therefore from different proton beam line 636 
designs. The used technique can alter the neutron dose in the order of magnitudes, 637 
whereas other factors have a smaller impact. This difference is getting less important with 638 
new proton therapy facilities, as mostly beam scanning nozzles are being installed 639 
nowadays. Still it can be seen that higher proton beam energies clearly lead to higher 640 
neutron doses and the neutron dose is higher closer to the primary proton beam. It has 641 
been confirmed, that in comparison to the total stray doses in photon therapy, the out-of-642 
field neutron dose in proton pencil beam scanning is relatively small. Concerning the 643 
biological effectiveness of neutrons, recent studies have not provided many new insights, 644 
but were able to confirm that the energy range around 1 MeV seems to be the most 645 
effective one. It has also been shown that this energy range is the dominant one for 646 
neutrons in the mixed field of stray radiation in proton therapy. 647 
Analytical models of neutron exposure from proton treatment plans have made a lot of 648 
progress. Now, different analytical models for active and passive proton delivery systems 649 
exist. Additionally, it has been shown that they can be integrated into treatment planning 650 
systems to efficiently predict the three-dimensional neutron dose distribution in the 651 
patient. This does open up the possibility to include in the future, beside the proton dose 652 
distribution, also the neutron dose in the process of finding the best treatment plan for a 653 
patient in proton therapy. 654 
In general, the publications in the last few years reported low neutron doses, especially in 655 
proton pencil beam scanning therapy. Together with the current knowledge about neutron 656 
RBE, it is therefore likely that the neutron dose has a small impact on the induction of 657 
second primary cancers for proton therapy patients. Even more, a reduction in second 658 
cancer risk for active and passive proton therapy is predicted by current models when 659 
compared to photon treatments. This is also in general agreement with current 660 
epidemiological results. It is therefore especially unlikely that an increase in second cancer 661 
rates will be observed from contemporary proton therapy, compared to the patients who 662 
have been treated with different radiation modalities within the past 20 years. 663 
In order to properly assess the risk of second primary cancer from neutron exposures, two 664 
requirements must be met. Firstly, the input to the risk models, the neutron doses, must be 665 
as precise as possible. Ideally, organ specific absorbed doses are used as input to cancer 666 
risk assessments. This data is still mostly missing and remains a topic, which needs to be 667 
investigated more. Only accurate neutron doses can lead to improved risk estimates, 668 
independent of the precision of the risk models. Over-simplified or incomplete dose 669 
estimates must not be used to calculate cancer risk for patients in radiation therapy. Monte 670 
Carlo simulations and realistic computational phantoms will continue to be a very valuable 671 
tool for this task. One of the big advantages is the possibility to directly evaluate the 672 
neutron fluence as a function of energy, which is linked to the biological effectiveness of 673 






















































































needs to be known for risk models to successfully predict the cancer risk. Currently the 675 
uncertainties are still too high and it is therefore necessary to gain more knowledge on the 676 
RBE of neutrons with regard to cancer induction. Future studies will have to further 677 
investigate the dependence of the neutron RBE on neutron dose, energy, dose rate, 678 
biological tissue, size, and age of the patient. 679 
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